Micro-metastases into the uterine leiomyoma from invasive ductal breast cancer under adjuvant tamoxifen therapy: case report

Metastasis of breast cancer to the uterus is extremely rare. However, breast cancer is the leading tumor metastasizing from extragenital organs to the uterus. The most common signs of uterine metastasis are bleeding and mass effect. Tamoxifen use is known to increase risk of endometrial cancer. Immunohistochemical staining with GCDFP can be useful in differentiating primary uterine tumors from breast cancer metastasis. Metastasis to the uterus has been reported to worsen the prognosis. Although hysterectomy has been effective on survival, treatment modality to be used in the presence of other systemic metastases is not clear. Locoregional treatments can be used in oligometastatic cases. In addition, removal of solitary organ metastasis together with bone metastasis provides improvement in survival.

Uterine leiomyoma; Micrometastasis; Breast cancer

[1] Shibuya K., Mathers C.D., Boschi-Pinto C., Lopez A.D., Murray C.J.L.: “Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000”. BMC Cancer, 2002, 2, 37.

[2] Pagani O., Senkus E, Wood W., Colleoni M., Cufer T., Kiyriaiakides S. et al.: “International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?”. J. Natl. Cancer Inst., 2010, 102, 456.

[3] Piura B., Yanai-Inbar I., Rabinovich A., Zalmanov S., Goldstein J.: “Abnormal uterine bleeding as a presenting sign of metastases to the uterine corpus, cervix and vagina in a breast cancer patient on tamoxifen therapy”. Eur. J. Obstet. Gynecol. Biol. Reprod., 1999, 83, 57.

[4] Kumar N.B., Hart W.R.: “Metastases to the uterine corpus from extragenital cancers. A clinicopathologic study of 63 cases”. Cancer, 1982, 50, 2163.

[5] di Bonito L., Patriarca S., Stanta G., Delendi M.: “Uterine metastases of extragenital carcinomas”. Rev. Fr. Gynecol. Obstet., 1985, 80, 21.

[6] Lamovec J., Bracko M.: “Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study”. J. Surg. Oncol., 1991, 48, 8.

[7] Le Bouëdec G., Kauffmann P., De Latour M., Fondrinier E., Curé H., Dauplat J.: “Uterine metastasis of breast cancer. Report of 8 cases”. J. Gynecol. Obstet. Biol. Reprod. (Paris), 1991, 20, 349.

[8] Le Bouedec G., de Latour M., Kauffmann P., Reynaud P., Fonck Y., Dauplat J., Service de Chirurgie, Centre Jean Perrin, Clermont-Ferrand: “Uterine metastases originating from breast cancer. Apropos of 12 cases”. Arch. Anat. Cytol. Pathol., 1993, 41, 140.

[9] Kondo N.I., Yoshida S., Kajiyama H., Nagasaka T., Uematsu T.: “Metastasis of breast cancer to a uterine leiomyoma”. Breast Cancer, 2009, 16, 157.

[10] Greenberg P.A., Hortobagyi G.N., Smith T.L., Ziegler L.D., Frye D.K., Buzdar A.U.: “Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer”. J. Clin. Oncol., 1996, 14, 2197.

[11] Ly B.H., Nguyen N.P., Vinh-Hung V., Rapiti E., Vlastos G.: “Loco-regional treatment in metastatic breast cancer patients: is there a survival benefit?”. Breast Cancer Res. Treat., 2010, 119, 537.

[12] Pocard M., Pouillart P., Asselain B., Falcou M.C., Salmon R.J.: “Hepatic resection for breast cancer metastases: results and prognosis (65 cases)”. Ann. Chir., 2001, 126, 413.

[13] Yoshimoto M., Tada T., Saito M., Takahashi K., Uchida Y, Kasumi F.: “Surgical treatment of hepatic metastases from breast cancer”. Breast Cancer Res. Treat., 2000, 59, 177.

[14] Swerdlow A.J., Jones M.E., British Tamoxifen Second Cancer Study Group: “Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study”. J. Natl. Cancer Inst., 2005, 97, 375.

[15] Early Breast Cancer Trialists' Collaborative Group (EBCTCG): “Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials”. Lancet, 2005, 365, 1687.

[16] Runowicz C.D.: “Gynecologic surveillance of women on tamoxifen: first do no harm”. J. Clin. Oncol., 2000, 18, 3457.

[17] Dabbs D.J.: “Immunohistology of metastatic carcinoma of unknown primary”. In: Diagnostic Immunohistochemistry, Dabbs D.J. (ed.). 2nd ed., Churchill Livingstone/Elsevier, 2006.

[18] Wick M.R., Lillemoe T.J., Copland G.T., Swanson P.E., Manivel J.C., Kiang D.T.: “Grosscystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin”. Hum. Pathol., 1989, 20, 281.

[19] Sasaki E., Tsunoda N., Hatanaka Y., Mori N., Iwata H., Yatabe Y. Mod. “Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers”. Pathol., 2007, 20, 208.

[20] Spiro R.K.: “Breast cancer metastatic to uterine leiomyoma”. J. Med. Soc. N.J., 1979, 76, 285.

[21] Afriat R., Lenain H., Vuagnat C., Michenet P., Luthier F., Maitre F. et al.: “Metastasis of breast cancer to a uterine leiomyoma (in French with English abstract)”. J. Gynecol. Obstet. Biol. Rep. (Paris), 1993, 22, 243.

[22] Charvolin J.Y., Salmon R.J., Pecking A., Mareschal V.: “Positron emission tomography detection of breast cancer metastasis to the uterus”. Obstet. Gynecol., 2002, 99, 915.

[23] Sugiyama T., Toyoda N., Nose J., Kihira N., Ando Y., Ishihara A.: “Breast cancer metastatic to uterine leiomyoma: a case report”. J. Obstet. Gynaecol., 1995, 21, 349.

[24] Minelli L., Romagnolo C., Giambanco L., Bongiorno E.: “Uterine leiomyoma metastasis as a first sign of breast cancer”. J. Am. Assoc. Gynecol. Laparosc., 1998, 5, 213.